Successful Treatment of MuSK Antibody-Positive Myasthenia Gravis with Rituximab
JOURNAL OF CHILD - COCUK DERGISI, cilt.25, sa.3, ss.172-175, 2025 (ESCI, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 25 Sayı: 3
- Basım Tarihi: 2025
- Doi Numarası: 10.26650/jchild.2025.1704940
- Dergi Adı: JOURNAL OF CHILD - COCUK DERGISI
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.172-175
- Eskişehir Osmangazi Üniversitesi Adresli: Evet
Özet
Muscle-specific tyrosine kinase antibody-associated myasthenia gravis (MuSK-MG) is a rare subtype of MG distinguished by recurring relapses and a clinical history unresponsive to conventional therapies. Rituximab, a monoclonal antibody that targets CD20+ B cells, has effectively induced long-term remission in adults. We report a pediatric MuSK-MG patient who exhibited a favourable response to rituximab following the ineffectiveness of steroid therapy and acetylcholinesterase inhibitor (AChEI) therapy.